



Ingeborg Stalmans

Full Professor in Neurosciences, Ophthalmology

1998 Master in Medicine, greatest distinction, KU Leuven

2002 PhD in Biomedical Sciences, KU Leuven

2003 Clinical specialization in Ophthalmology, KU Leuven

2004 Subspecialization in Glaucoma, KU Leuven

A. Positions and Honours

- 2005-present **FWO mandate** for fundamental research at the KU Leuven
- 2006-present **Head of Glaucoma Clinic**, University hospitals Leuven
- 2016-present **Head of Research Group Ophthalmology**, KU Leuven
- 2013-present **Full Professor in Ophthalmology**, KU Leuven
 - 21 Post-Docs/ PhDs, 23 Master Theses
- **Associate Editor**
 - Acta Ophthalmologica,
 - Ophthalmologica
 - Journal of Ophthalmology
- **Board member**
 - Governor for the World Glaucoma Association (WGA)
 - Vice President of the European Glaucoma Society (EGS)
 - President of the Belgian Glaucoma Society (BGS)
 - Co-founder of the Belgian Glaucoma patients society
- **Member**
 - Royal Academy of Medicine
 - Belgisch Oftalmologisch Gezelschap (BOG)
 - American Academy of Ophthalmology
 - International Glaucoma Society
 - Ocular Blood Flow Research Association
 - International Ocular Circulation Society
 - European Society for Microcirculation
- **Prizes:**
 - **33 times the Prize of the "Funds for Research in Ophthalmology"** (1998-2017)
 - **Other prizes:** 4 times Pfizer Research Award (2006-2010), Glaxo Smith-Kline prize for medical sciences 2004, FWO Krediet aan navorsers 2006-2007, "Gouden Pluim" award from the patient organisation "Uilennest" 2008, EVER travel grant 2010, ARVO travel grant twice (2010, 2012), Best Poster OB 2013, Prize of the King Boudewijn Foundation 2016, BOCCS 2020 Laureate, Fonds John W Mouton Pro Retina 2020

B. Publications

Number of peer reviewed publications: **155** + 3 book chapters

Examples of relevant publications:

Combination of snapshot hyperspectral retinal imaging and optical coherence tomography to identify Alzheimer's disease patients.

Lemmens S, Van Craenendonck T, Van Eijgen J, De Groef L, Bruffaerts R, de Jesus DA, Charle W, Jayapala M, Sunaric-Mégevand G, Standaert A, Theunis J, Van Keer K, Vandebulcke M, Moons L, Vandenberghe R, De Boever P, **Stalmans I**. *Alzheimers Res Ther*. 2020 Nov 10;12(1):144. doi: 10.1186/s13195-020-00715-1.PMID: 33172499

Integrin $\alpha 5\beta 1$ Inhibition by CLT-28643 Reduces Postoperative Wound Healing in a Mouse Model of Glaucoma Filtration Surgery.

Van Bergen T, Zahn G, Caldirola P, Fsadni M, Caram-Lelham N, Vandewalle E, Moons L, **Stalmans I**. *Invest Ophthalmol Vis Sci*. 2016 Nov 1;57(14):6428-6439. doi: 10.1167/iovs.16-19751.PMID: 27893886

The Combination of PIGF Inhibition and MMC as a Novel Anti-Scarring Strategy for Glaucoma Filtration Surgery.

Van Bergen T, Jonckx B, Moons L, Feyen JH, **Stalmans I**. *Invest Ophthalmol Vis Sci*. 2016 Aug 1;57(10):4347-55. doi: 10.1167/iovs.16-19725.PMID: 27556218

AMA0428, A Potent Rock Inhibitor, Attenuates Early and Late Experimental Diabetic Retinopathy.

Hollanders K, Hove IV, Sergeys J, Bergen TV, Lefevere E, Kindt N, Castermans K, Vandewalle E, van Pelt J, Moons L, **Stalmans I**. *Curr Eye Res*. 2017 Feb;42(2):260-272. doi: 10.1080/02713683.2016.1183030. Epub 2016 Jul 11.PMID: 27399806

Rho kinase inhibitor AMA0526 improves surgical outcome in a rabbit model of glaucoma filtration surgery.

Van de Velde S, Van Bergen T, Vandewalle E, Kindt N, Castermans K, Moons L, **Stalmans I**. *Prog Brain Res*. 2015;220:283-97. doi: 10.1016/bs.pbr.2015.04.014. Epub 2015 Jun 30.PMID: 26497796

The Role of LOX and LOXL2 in the Pathogenesis of an Experimental Model of Choroidal Neovascularization.

Van Bergen T, Spangler R, Marshall D, Hollanders K, Van de Veire S, Vandewalle E, Moons L, Herman J, Smith V, **Stalmans I**. *Invest Ophthalmol Vis Sci*. 2015 Aug;56(9):5280-9. doi: 10.1167/iovs.14-15513.PMID: 26258612

Inhibition of Rho-Associated Kinase Prevents Pathological Wound Healing and Neovascularization After Corneal Trauma.

Sijnave D, Van Bergen T, Castermans K, Kindt N, Vandewalle E, Stassen JM, Moons L, **Stalmans I**. *Cornea*. 2015 Sep;34(9):1120-9. doi: 10.1097/ICO.0000000000000493.PMID: 26075454

The effect of AMA0428, a novel and potent ROCK inhibitor, in a model of neovascular age-related macular degeneration.

Hollanders K, Van Bergen T, Kindt N, Castermans K, Leysen D, Vandewalle E, Moons L, **Stalmans I**. *Invest Ophthalmol Vis Sci*. 2015 Jan 27;56(2):1335-48. doi: 10.1167/iovs.14-15681.PMID: 2562696

C. Research Support

Title	Funding agency	Period	Role	Amount (Euros)
C3 Hercules project 'Vision Core Leuven: a service platform for compound screening and disease modeling in the eye'	KUL	2019	Copromotor	473.000
Joint PhD KUL-Porto Joao Barbosa Breda	EGS	2018-2019	Copromotor	18.000
Postdoc Danilo Andrade Jesus	KUL	2019-2020	Promotor	+ - 85.000
'ATTRACT'	HERALD	2019-2020	Partner	100.000
JPND 'BRAINSTORM'	EU (via FWO)	2021-2024	Partner	350.000
EraNet JTC CVD 'ENRICH'	EU (via FWO)	2021-2024	Coordinator	200.000
Predocctoral mandate Jan Van Eijgen	FWO	2020-2024	Promotor	80.000
'BEGONIA'	FRO	2020-2022	Coordinator	120.000
2 Joint PhDs	KUL-Melbourne university	2021-2024	Promotor (PhD KUL) Co-promotor (PhD AU)	160.000
Postdoc Eirini Christinaki	Mission Lucidity	2020-2022	Promotor	80.000